NOVO NORDISK A S - 14 Jul 2025 SCHEDULE 13G/A Report for Innate Pharma SA Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares) (IPHA)

Filing Manager
NOVO NORDISK A S
Reporting Manager
Novo Nordisk A/S
Security
Innate Pharma SA Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares)
Symbol
IPHA
Shares outstanding
92,182,891 shares
Disclosed Ownership
8,895,649 shares
Ownership
9.6%
Form type
SCHEDULE 13G/A
Filing time
21 Oct 2025, 08:00:17 UTC
Date of event
14 Jul 2025
Next filing
04 Mar 2026
SEC
View on sec.gov

Sponsored

Quoteable Key Fact

"NOVO NORDISK A S disclosed 9.6% ownership in Innate Pharma SA Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares) (IPHA) on 14 Jul 2025."

Quick Takeaways

  • NOVO NORDISK A S filed SCHEDULE 13G/A for Innate Pharma SA Ordinary Shares, nominal value (euro) 0.05 per share (including ordinary shares represented by American Depositary Shares) (IPHA).
  • Disclosed ownership: 9.6%.
  • Date of event: 14 Jul 2025.

What Changed

  • No earlier schedule filing is available for direct comparison.
  • Current filing was accepted on 21 Oct 2025, 08:00.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Official SEC Source

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (1)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
Novo Nordisk A/S 9.6% 8,895,649 8,895,649 0 /s/ Karsten Munk Knudsen Karsten Munk Knudsen, Chief Financial Officer

Sponsored